Gilead Q3 Revenue Rises 6.8% to $8.3 Billion, Guidance Tops Estimates
Gilead Sciences reported Q3 2026 sales of $8.3 billion, up 6.8% year on year. Full-year revenue guidance of $31.15 billion at the midpoint was 1.3% above analysts’ estimates.
Biopharmaceutical company Gilead Sciences NASDAQ:GILDreported Q3 2026 results exceeding the market’s revenue expectations, with sales up 6.8% year on year to $8.3 billion. The company’s full-year revenue guidance of $31.15 billion at the midpoint came in 1.3% above analysts’ estimates. Its non-GAAP…